YM872 (zonampanel), t-PA (alteplase)
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Ischemic Stroke
Conditions
Acute Ischemic Stroke
Trial Timeline
Dec 1, 2000 → Jan 1, 2003
NCT ID
NCT00044057About YM872 (zonampanel), t-PA (alteplase)
YM872 (zonampanel), t-PA (alteplase) is a phase 2 stage product being developed by Astellas Pharma for Acute Ischemic Stroke. The current trial status is completed. This product is registered under clinical trial identifier NCT00044057. Target conditions include Acute Ischemic Stroke.
What happened to similar drugs?
20 of 20 similar drugs in Acute Ischemic Stroke were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00044057 | Phase 2 | Completed |
Competing Products
20 competing products in Acute Ischemic Stroke